CCL2 and myalgic encephalomeyelitis/chronic fatigue syndrome: This alongside recent reports of increased MCP1 plasma levels in ME/CFS (83), suggests a reduction of MCP1 at healthiest time point might be linked to reduced neuroinflammation (94), improved blood-brain barrier permeability (95), diminished neuronal sensitization, and alleviated endothelial dysfunction (96).